Viral targets for antisense oligonucleotides: A mini review

Antiviral Research

Volumn 37, Issue 2, 1998, Pages 67-81

  Field, A Kirk ^a,b,c  

^a HYBRIDON INC   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c NONE   (United States)

Author keywords

Antisense; Design selective inhibitors; Oligonucleotides; Selective inhibitors

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; AVIAN LYMPHOMATOSIS HERPETOVIRUS; CYTOMEGALOVIRUS; DRUG DESIGN; DRUG TARGETING; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR INTERACTION; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA PROCESSING; SHORT SURVEY; VIRUS INHIBITION; VIRUS TRANSCRIPTION;

AVES; CYTOMEGALOVIRUS; HEPATITIS B VIRUS; HERPES; HERPETOVIRUS; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; MARDIVIRUS; PAPILLOMAVIRUS; RESPIRATORY SYNCYTIAL VIRUS; SIMPLEXVIRUS;

EID: 0032006475     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)00060-0     Document Type: Article

References (56)

1. Agrawal, S., Temsamani, J., 1996. Comparative pharmacokinetics of antisense oligonucleotides. In: Agrawal, S. (Ed.), Antisense Therapeutics. Humana, Totowa, NJ, pp. 247-270.
2. Anazodo, M.I., Wainberg, M.A., Friesen, A.D., Wright, J.A., 1995. Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome. J. Virol. 69, 1794-1801.
3. Austermann, S., Kruhoffer, M., Grosse, F., 1992. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by 3′-blocked oligonucleotide primers. Biochem. Pharmacol. 43, 2581-2589.
4. Azad, R.F., Driver, V.B., Tanaka, K., Crooke, R.M., Anderson, K.P., 1993. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37, 1945-1954.
5. Bishop, J.S., Guy-Caffey, J.K., Ojwang, J.O., Smith, S.R., Hogan, M.E., Cossum, P.A., Rando, R.F., Chaudhary, N., 1996. Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J. Biol. Chem. 271, 5698-5703.
6. Bordier, B., Hélène, C., Barr, P.J., Litvak, S., Sarih-Cottin, L., 1992. In vitro effect of antisense oligonucleotides on human immunodeficiency virus type 1 reverse transcription. Nucleic Acids Res. 20, 5999-6006.
7. Chen, T.Z., Lin, S.B., Wu, J.C., Choo, K.B., Au, L.C., 1996. A method for screening antisense oligodeoxyribonucleotides effective for mRNA translation-arrest. J. Biochem. (Tokyo) 119, 252-255.
8. Cowsert, L.M., Fox, M.C., Zon, G., Mirabelli, C.K., 1993. In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob. Agents Chemother. 37, 171-177.
9. Crooke, S.T., Bennett, C.F., 1996. Progress in antisense oligonucleotide therapeutic. Annu. Rev. Pharmacol. Toxicol. 36, 107-129.
10. Crooke, S.T., Graham, M.J., Zuckerman, J.E., Brooks, D., Conklin, B.S., Cummins, L.L., Greig, M.J., Guinosso, C.J., Kornblust, D., Manoharan, M., Sasmor, H., Schleich, T., Tivel, K.L., Griffey, R.H., 1996. Pharmacokinetic properties of several novel oligonucleotide analogues in mice. J. Pharm. Exp. Ther. 277, 923-937.
11. Daibata, M., Enzinger, E.M., Monroe, J.E., Kilkuskie, R.E., Field, A.K., Mulder, C., 1996. Antisense oligodeoxynucleotides against the BZLF1 transcript inhibit induction of productive Epstein-Barr virus replication. Antiviral Res. 29, 243-260.
12. Fennewald, S.M., Mustain, S., Ojwang, J., Rando, R.F., 1995. Inhibition of herpes simplex virus in culture by oligonucleotides composed entirely of deoxyguanosine and thymidine. Antiviral Res. 26, 37-54.
13. Field, A.K., Goodchild, J., 1995. Antisense oligonucleotides: Rational drug design for genetic pharmacology. Exp. Opin. Invest. Drugs 4, 799-821.
14. Frank, B.L., Trainor, B.L., Cocuzza, A. J., Hobbs, F.W., Chidester, D.R., 1993. Selection of mRNA sequences for targeting with antisense reagents (Abstract). In: Proceedings of the International Conference on Nucleic Acid Medical Applications. NAMA Cancun, Mexico, Publ. by Nucleic Acid Med. Applic. pp. 4-14.
15. Frank, B.L., Goodchild, J., 1996. In: Turner, P.C. (Ed.) Ribozyme Protocols. Humana, Totowa, NJ.
16. Galasso, G.J., Whitley, R.J. Merigan, T.C. (Eds.) 1990. Antiviral Agents and Viral Diseases of Man, Raven, New York.
17. Gao, W., Stein, C.A., Cohen, J.S., Dutschman, G.E., Cheng, Y.-C., 1989. Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase. J. Biol. Chem. 264, 11521-11526.
18. Han, J., Zhu, Z., Hsu, C., Finley, W.H., 1994. Selection of antisense oligonucleotides on the basis of genomic frequency of the target sequence. Antisense Res. Dev. 4, 53-65.
19. Hatta, T., Kim, S.-G., Nakashima, H., Yamamoto, N., Sakamoto, K., Yokoyama, S., Takaku, H., 1993. Mechanisms of the inhibition of reverse transcription by unmodified and modified antisense oligonucleotides. FEBS Lett. 330, 161-164.
20. Ho, S.P., Britton, D.H.O., Stone, B.A., Behrens, D.L., Leffet, L.M., Hobbs, F.W., Miller, J.A., Trainor, G.L., 1996. Potent antisense oligonucleotides to the human multi-drug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 24, 1901-1907.
21. Huang, D.P., 1991. In: van Hasselt, C.A., Gibb, A.G., (Eds.), Nasopharyngeal Carcinoma. The Chinese University Press, Hong Kong. pp. 23-36.
22. Jairath, S., Brown Vargas, P., Hamlin, H.A., Field, A.K., Kilkuskie, R.E., 1997. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res. 33, 201-213.
23. Jeffries, D.J., De Clercq, E., (Eds.) 1995. Antiviral Chemotherapy. Wiley, New York.
24. Kawamura, M., Hayashi, M., Furuichi, T., Nonoyama, M., Isogai, E., Namioka, S., 1991. The inhibitory effects of oligonucleotides, complementary to Marek's disease virus mRNA transcribed from the BamHI-H region, on the proliferation of transformed lymphoblastoid cells, MDCC-MSB1. J. Gen. Virol. 72, 1105-1111.
25. Kean, J.M., Kipp, S.A., Miller, P.S., Kulka, M., Aurelian, L., 1995. Inhibition of herpes simplex virus replication by antisense oligo-2′-O-methylribonucleoside methylphosphonates. Biochemistry 34, 14617-14620.
26. Kilkuskie, R.E., Field, A.K., 1997. Antisense inhibition of virus infections. In: August, J.T. (Ed.), Gene Therapy, Advances in Pharmacology vol. 40, pp. 437-483.
27. Korba, B.E., Gerin, J.L., 1995. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Antiviral Res. 28, 225-242.
28. Krieg, A.M., Yi, A.-E., Matson, S., Waldschmidt, T.J., Bishop, G.A., Teasdale, R., Koretzky, G.A., Klinman, D.M., 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
29. Kulka, M., Smith, C.C., Aurelian, L., Fishelevich, R., Meade, K., Miller, P., Ts'O, P.O.P., 1989. Site specificity of the inhibitory effects of oligonucleoside methyphosphonates complementary to the acceptor splice junction of herpes simples virus type 1 immediate early mRNA 4. Proc. Natl. Acad. Sci. U.S.A. 86, 6868-6872.
30. Kulka, M., Wachsman, M., Miura, S., Fishelevich, R., Miller, P.S., Ts'O, P.O.P., Aurelian, L., 1993. Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate early mRNAs 4 and 5. Antiviral Res. 20, 115-130.
31. Kulka, M., Smith, C.C., Levis, J., Fishelevich, R., Hunter, J.C.R., Cushman, C.D., Miller, P.S., Ts'O, P.O.P., Aurelian, L., 1994. Synergistic antiviral activities of oligonucleoside methylphosphonates complementary to herpes simplex virus type 1 immediate-early mRNAs 4, 5, and 1. Antimicrob. Agents Chemother. 38, 675-680.
32. Kulka, M., Aurelian, L., 1995. Antiviral activity of and oligo(nucleoside methylphosphonate) that targets HSV-1 immediate-early pre-mRNA 4,5 is augmented by cotreatment with replication-defective adenovirus. Antisense Res. Dev. 5, 243-249.
33. Lewis, E.J., Szymkowski, D.E., Greenfield, I.M., Kreider, J.W., Roberts, P.C., Frank, B.L., Wolfe, J.L., Kilkuskie, R.E., Mills, J.S., 1997. Identification of an antisense olignucleotide with in vivo activity against human papillomavirus. 2. Efficacy against benign human genital condyloma in a mouse xenograft model. Antiviral Res. 34, A72.
34. Martin, R., Pari, G., Marquis, J., Dvorchik, B., Grindel, J., Schechter, P., Cohen, A., Bourque, A., Guinot, P., 1997. Early studies with GEM 1322, a metabolically-stable antisense oligonucleotide (ODN) for intravitreal injection or systemic treatment of cytomegalovirus (CMV) infections, at Carbohydrate Based HCMV Therapeutics - 213th Am. Chem. Soc. Natl. Meet., in press.
35. Offensperger, W.B., Offensperger, S., Walter, E., Teubner, K., Igloi, G., Blum, H.E., Gerok, W., 1993. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. Eur. Mol. Biol. Organisation J. 12, 1257-1262.
36. Ojwang, J.O., Buckheit, R.W., Pommier, Y., Mazumder, A., De Vreese, K., Esté, J.A., Reymen, D., Pallansch, L.A., Lackman-Smith, C., Wallace, T.L., De Clercq, E., McGrath, M.S., Rando, R.F., 1995. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39, 2426-2435.
37. Pagano, J.S., 1995. Epstein-Barr virus:therapy of ative and latent infection. In: Jeffries, D.J., De Clercq, E., (Eds.), Antiviral Chemotherapy. Wiley, New York, pp. 155-195.
38. Pagano, J.S., Jimenez, G., Sung, N.S., Raab-Traub, N., Lin, J.-C., 1992. Epstein-Barr viral latency and cell immortalization as targets for antisense oligomers. Ann. New York Acad. Sci. 660, 107-116.
39. Pari, G.S., Anders, D.G., 1993. Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus ori-Lyt-dependent DNA replication. J. Virol. 67, 6979-6988.
40. Pari, G.S., Field, A.K., Smith, J.A., 1995. Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob. Agents Chemother. 39, 1157-1161.
41. Peyman, A., Helsberg, M., Kretzschmar, G., Mag, M., Grabley, S., Uhlmann, E., 1995. Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. Biol. Chem. 376, 195-198.
42. Poddevin, B., Meguenni, S., Elias, I., Vasseur, M., Blumenfeld, M., 1994. Improved anti-herpes simplex virus type 1 activity of a phosphodiester antisense oligonucleotide containing a 3′-terminal hairpin-like structure. Antisense Res. Dev. 4, 147-154.
43. Roberts, P.C., Frank, B.L., Boldt, S.E., Walther, D.M., Wolfe, J.L., Kilkuskie, R.E., Szymkowski, D.D., Greenfield, I.M., Sullivan, V., Mills, J.S., 1997. Identification of an antisense olignucleotide with in vivo activity against human papillomavirus. 1. In vitro evaluation of oligonucleotides. Antiviral Res. 34, A71.
44. Roth, G., Curiel, T., Lacy, J., 1994. Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 84, 582-587.
45. Sczakiel, G., Homann, M., Rittner, K., 1993. Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1. Antisense Res. Devel. 3, 45-52.
46. Shah, K.V., Howley, P.M., 1996. In: Fields, B.N., Knipe, D.M., Howley, P.M. (Eds.), Virology, 3rd edn. Lippicott-Raven, Philadelphia, pp. 2077-2110.
47. Smith, J.A., Pari, G.S., 1995. Expression of human cytomegalovirus UL36 and UL37 genes is required for viral DNA replication. J. Virol. 69, 1925-1931.
48. Stein, C.A., Krieg, A.M., 1994. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4, 67-69.
49. Stein, C.A., Cleary, A.M., Yakubov, L., Lederman, S., 1993. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. Antisense Res. Devel. 3, 19-31.
50. Stephenson, M.L., Zamecnik, P.C., 1978. Inhibition of rous sarcoma virus viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U.S.A. 75, 285-288.
51. Stull, R.A., Taylor, L.A., Szoka, F.C., 1992. Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices. Nucleic Acids Res. 20, 3501-3508.
52. Temsamani, J., Agrawal, S., 1996. Antisense oligonucleotides as antiviral agents. Adv. Antiviral Drug Design 2, 1-39.
53. Townsend, L.B., Devivar, R.V., Turk, S.R., Massiri, M.R., Drach, J.C., 1995. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(β-D-ribofuranosyl) benzimidazoles. J. Med. Chem. 38, 4098-4105.
54. Wyatt, J.R., Vickers, T.A., Roberson, J.L., Buckheit, R.W. Jr., Klimkait, T., DeBaets, E., Davis, P.W., Rayner, B., Imbach, J.L., Ecker, D.J., 1994. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. U.S.A. 91, 1356-1360.
55. Zamecnik, P.C., Stephenson, M.L., 1978. Inhibition of rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 75, 280-284.
56. Zelphati, O., Imbach, J.-L., Signoret, N., Zon, G., Rayner, B., Leserman, L., 1994. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit of HIV-1 by several different mechanisms. Nucleic Acids Res. 22, 4307-4314.